您的位置:PharmaNews 研发动态 正文
内容搜索
热门内容
推荐内容
最新内容
反馈意见和建议

Researchers Solve Mystery of Uner Tan Syndrome with Targeted Next-Generation Sequencing Using Roche NimbleGen Sequence Capture and 454 Sequencing Systems
本文章共6145字,分4页,当前第1页,快速翻页:

MADISON, Wis.--(BUSINESS WIRE)--Jul 29, 2010 - A team of researchers from leading universities in Turkey and the United States have reported that they have identified the genetic mutation responsible for the Uner Tan Syndrome (UTS) using advanced genetic capture and sequencing technologies from Roche (SWX:RO)(SWX:ROG)(Pink Sheets: RHHBY). The combined genomic technologies enabled the team of scientists to identify the causative mutation of this debilitating disease after years of mystery. The study was presented by Suleyman Gulsuner, M.D. from Bilkent University, Turkey during the European Human Genetics Conference recently held in Gothenburg, Sweden at which he was awarded the prestigious Isabelle Oberlé Award for outstanding work in the field of genetics of mental retardation.

Uner Tan Syndrome is a debilitating condition that causes those affected to walk with a quadruped gait, using their feet and the palms of their hands while also suffering from severe mental retardation. This syndrome attracted worldwide attention and was featured in the 2006 BBC2 documentary The Family That Walks On All Fours. In addition to the initial family, other families with the same syndrome have been reported in Turkey as well as in Iraq, Iran and Brazil. Initial mapping studies indicated genetic heterogeneity. The scientific group, led by Prof. Tayfun Özçelik, M.D. at Bilkent University, identified the first gene in 2008 (Proc Natl Acad Sci U S A, 105:4232-6). However, the cause of this disorder in the original family featured in the BBC documentary remained unclear and theories regarding the contribution of genetic and environmental factors have been postulated. To identify the genetic basis, scientists have focused their search on a specific region on chr 17p13 in the genome. However, finding the disease causing mutation in the more than 7 million DNA bases within this region has presented an enormous challenge.

Using Roche NimbleGen's Sequence Capture technology and the GS FLX System from 454 Life Sciences, a Roche company, the ~ 7 Mb targeted candidate region from two affected and two carrier individuals were quickly extracted from the genome and sequenced. Trimming of the candidate mutations found in the region led to a list of four final candidates based on gene function and Mendelian disease models. Out of these four candidates, three were excluded by further screening 300 healthy controls. In the end, a single mutation was discovered from this study as the genetic basis for Uner Tan Syndrome in the affected family.

“Human genomics is enjoying a most productive period in the identification of genes associated with rare diseases thanks to next generation sequencing technologies. The gap between the identification of a disease locus and the actual documentation of causative mutations was a daunting task until recently; presenting a serious bottleneck in medical genetics studies” explained Prof. Tayfun Özçelik, “However, now as we celebrate the 10


 

 

点这里复制本页地址     发送给您QQ/MSN上的好友


相关文章

  Shionogi Inc. Announces FDA Approval of

  Abraxis BioScience and Specialised Thera

  Abbott's Simcor ( niacin extended-releas

  FDA Approves Drug for Chronic Drooling i

  Quintiles Announces New European Headqua

  Covance Reports Second Quarter Revenue o

  Commonwealth Biotechnologies, Inc. Provi

WaferGen Announces Purchase of SmartChip

Plant Compound Resveratrol Shown to Supp

New pathway to Parkinson's and Alzheimer

deCODE Shows how Genetic Risk of Kidney

Bionovo to Advance Menerba to Phase 3 Cl

Geron to Proceed with First Human Clinic

Orexigen Therapeutics Announces Publicat

Basilea Pharmaceutica AG (CH) - Data on

Study Results Show That Oral Contracepti

勃林格殷格翰糖尿病药物linagliptin一项Ⅲ期

相关评论

    
本文章所属分类:首页 研发动态